Biomaterial-based antigen free vaccine and the use thereof
AssigneesPresident and Fellows of Harvard College, The General Hospital Corporation
InventorsAlexander J. Najibi, Nisarg J. Shah, Hua Wang, David J. Mooney, David T. Scadden
Life of this patent
Estimating the term…
Abstract
Disclosed herein are vaccine compostions and method to use the same. The compositions and methods disclosed herein provide means to prevent and/or treat a variety of cancers.
Claims20
A vaccine composition for treating a hematological malignancy, comprising:
- a porous scaffold,
- a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;
- an adjuvant, wherein the adjuvant comprises a CpG-ODN;
- a chemotherapeutic agent;
- and
- a cancer antigen, wherein the cancer antigen is one or both of a WT-1 peptide or an acute myeloid leukemia cancer cell lysate, and wherein the WT-1 peptide is not from a cancer cell lysate.
A method of treating an acute myeloid leukemia (AML) in a subject, comprising administering to the subject a vaccine composition, wherein the vaccine composition comprises
- a porous scaffold;
- a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;
- an adjuvant, wherein the adjuvant comprises a CpG-ODN;
- and
- a chemotherapeutic agent,
- thereby treating the AML.
A method of preventing or treating an acute myeloid leukemia (AML) in a subject, comprising administering to the subject a vaccine composition, wherein the vaccine composition comprises
- a scaffold;
- a cell recruitment composition, wherein the cell recruitment composition comprises a GM-CSF;
- an adjuvant, wherein the adjuvant comprises a CpG-ODN;
- a chemotherapeutic agent;
- and
- a cancer antigen, wherein the cancer antigen is one or both of a WT-1 peptide or an acute myeloid leukemia cancer cell lysate,
- thereby preventing or treating the AML.
Dependencies are inferred from the claim text.